Work

AML-251 Overall Survival (OS) With Intensive Chemotherapy (IC) vs Non-IC in Patients With Newly Diagnosed (ND) AML from the Connect® Myeloid Disease Registry Ineligible for Randomized Clinical Trials (RCT)

Year: 2022

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(22)01254-x

Authors: Harry P. Erba, Daniel A. Pollyea, Mikkael A. Sekeres, Guillermo Garcia-Manero, Karen Seiter, Irene S. DeGutis, Pavel Kiselev, Ali McBride, Edward Yu, Gail J. Roboz

Institutions: Duke University, University of Miami Health System, Sylvester Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, New York Medical College, Bristol-Myers Squibb (United States), NewYork–Presbyterian Hospital, Weill Cornell Medicine

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4296468285

Cites:

Cited by:

Related to: 10